As "the first enterprise to eat crabs", how will Nuohui Health maintain a strong development trend in the future?

Recently, Nuohui Health, the "first stock in early cancer screening in China", announced its financial report for the first half of 2022 as of June 30

Recently, Nuohui Health, the "first stock in early cancer screening in China", announced its financial report for the first half of 2022 as of June 30

According to the financial report, Nuohui's revenue and gross profit margin continued to grow strongly in the first half of the year, and the total revenue is expected to range from RMB 217.

According to the financial report, Nuohui's revenue and gross profit margin continued to grow strongly in the first half of the year, and the total revenue is expected to range from RMB 217.

Since its listing, Nuohui Health has received attention from people from all walks of life in the big health industry

Since its listing, Nuohui Health has received attention from people from all walks of life in the big health industry

In February 2021, Nuohui Health was listed on the Hong Kong stock market, and the opening price rose 185% to HK$76 per share, and the market value immediately exceeded 30 billion

In February 2021, Nuohui Health was listed on the Hong Kong stock market, and the opening price rose 185% to HK$76 per share, and the market value immediately exceeded 30 billion

The latest data shows that as of the close on August 12, Nuohui Health’s current share price is HK$22.

The latest data shows that as of the close on August 12, Nuohui Health’s current share price is HK$22.

As "the first enterprise to eat crabs", how will Nuohui Health maintain a strong development trend in the future?

As "the first enterprise to eat crabs", how will Nuohui Health maintain a strong development trend in the future?

Cancer Early Screening Market Geometry

Cancer Early Screening Market Geometry Cancer Early Screening Market Geometry Early Cancer Screening Market Geometry

China is a big country with cancer, and the number of cancer patients remains high

China is a big country with cancer, and the number of cancer patients remains high

According to a paper titled: Cancer statistics in China and United States, 2022: profiles, trends, and determinants published by the team of Professor Chen Wanqing from the National Cancer Center of the Chinese Academy of Medical Sciences and Peking Union Medical College Hospital in the English version of the Chinese Medical Journal:

According to a paper titled: Cancer statistics in China and United States, 2022: profiles, trends, and determinants published by the team of Professor Chen Wanqing from the National Cancer Center of the Chinese Academy of Medical Sciences and Peking Union Medical College Hospital in the English version of the Chinese Medical Journal:

In 2022, there will be approximately 4,820,000 and 2,370,000 new cancer cases and 3,210,000 and 640,000 cancer deaths in China and the United States, respectively

In 2022, there will be approximately 4,820,000 and 2,370,000 new cancer cases and 3,210,000 and 640,000 cancer deaths in China and the United States, respectively
.

Figure 1 Comparison of the number of new cancers in China and the United States

Figure 1 Comparison of the number of new cancers in China and the United States

Yaozhi Network Mapping

Yaozhi Network Mapping

This data means that the number of new cancer cases in China is about twice that of the United States, but the number of deaths is about five times that of the United States
.

This data means that the number of new cancer cases in China is about twice that of the United States, but the number of deaths is about five times that of the United States
.

Figure 2 Comparison of cancer deaths between China and the United States

Figure 2 Comparison of cancer deaths between China and the United States

Yaozhi Network Mapping

Yaozhi Network Mapping

Cancer has become an important cause of death in our country
.

Cancer has become an important cause of death in our country
.

Based on this, early cancer screening will bring great social and economic value
.

Based on this, early cancer screening will bring great social and economic value
.

According to the definition of WHO, early tumor screening refers to the use of quick and simple methods to screen out a very small number of high-risk groups (positive people) for tumors from a large number of people who have not yet developed symptoms.
It is the early detection link of tumor prevention
.

According to the definition of WHO, early tumor screening refers to the use of quick and simple methods to screen out a very small number of high-risk groups (positive people) for tumors from a large number of people who have not yet developed symptoms.
It is the early detection link of tumor prevention
.

Take Helicobacter pylori as an example
.

Take Helicobacter pylori as an example
.

According to statistics, Helicobacter pylori, which is classified as a "type I carcinogen", has infected nearly 700 million people in China
.

According to statistics, Helicobacter pylori, which is classified as a "type I carcinogen", has infected nearly 700 million people in China
.

Although listed as a clear carcinogen, eradication of Helicobacter pylori is not so terrible:

Although listed as a clear carcinogen, eradication of Helicobacter pylori is not so terrible:

After early screening, the eradication rate of quadruple drugs is as high as 94%, and the annual reinfection rate after radical treatment is only 1.
5%.
Based on long-term follow-up prediction, eradication of Helicobacter pylori can avoid two-thirds of gastric cancers
.

After early screening, the eradication rate of quadruple drugs is as high as 94%, and the annual reinfection rate after radical treatment is only 1.
5%.
Based on long-term follow-up prediction, eradication of Helicobacter pylori can avoid two-thirds of gastric cancers
.

Obviously, timely early screening of gastric cancer can greatly prolong the life cycle and reduce costs
.

Obviously, timely early screening of gastric cancer can greatly prolong the life cycle and reduce costs
.

According to an industry report released by CIC, China's cancer early screening industry is currently in its infancy and market education stage, and the user penetration rate is extremely low;

According to an industry report released by CIC, China's cancer early screening industry is currently in its infancy and market education stage, and the user penetration rate is extremely low;

It is estimated that the market potential will exceed RMB 200 billion by 2030, among which the fastest clinically developed early screening products for cancer are mainly colorectal cancer and liver cancer
.

It is estimated that the market potential will exceed RMB 200 billion by 2030, among which the fastest clinically developed early screening products for cancer are mainly colorectal cancer and liver cancer
.

The early cancer screening market is on the verge of exploding
.

The early cancer screening market is on the verge of exploding
.

"The first enterprise to eat crabs"

"The first enterprise to eat crabs" "The first enterprise to eat crabs" "The first enterprise to eat crabs"

From the mid-1970s to the approval of the first early cancer screening certificate by the State Food and Drug Administration in 2020, this road has taken nearly 50 years
.

From the mid-1970s to the approval of the first early cancer screening certificate by the State Food and Drug Administration in 2020, this road has taken nearly 50 years
.

And Nuohui Health has become the first early screening company to "take the lead"
.

And Nuohui Health has become the first early screening company to "take the lead"
.

In 2020, the State Food and Drug Administration issued China's first registration certificate for early cancer screening, and approved the registration application of "Chang Weiqing" under NovoHealth
.

In 2020, the State Food and Drug Administration issued China's first registration certificate for early cancer screening, and approved the registration application of "Chang Weiqing" under NovoHealth
.

It is reported that "Changweiqing" uses multi-target fecal FIT-DNA combined detection technology to detect KRAS gene mutation and BMP3/NDRG4 gene methylation and fecal occult blood combined detection kit for early cancer screening, which can clearly be used for high rectal cancer patients.
Screening of at-risk groups
.

It is reported that "Changweiqing" uses multi-target fecal FIT-DNA combined detection technology to detect KRAS gene mutation and BMP3/NDRG4 gene methylation and fecal occult blood combined detection kit for early cancer screening, which can clearly be used for high rectal cancer patients.
Screening of at-risk groups
.

Since then, Nuohui Health has launched the "first shot" in the field of early screening, which can be described as the "first enterprise that eats crabs" in China
.

Since then, Nuohui Health has launched the "first shot" in the field of early screening, which can be described as the "first enterprise that eats crabs" in China
.

At present, Nuohui Health has 3 products approved to be listed for profit, 2 products are under research, and the product pipeline is precisely focused on the field of early cancer screening
.

At present, Nuohui Health has 3 products approved to be listed for profit, 2 products are under research, and the product pipeline is precisely focused on the field of early cancer screening
.

Figure 3 Nuohui Health Product Pipeline

Figure 3 Nuohui Health Product Pipeline

Source: 2021 Annual Report

Source: 2021 Annual Report

puff pipe

puff puff puff puff

In January 2018, "Pupu Tube" obtained the second-class medical device registration certificate: 5 minutes insight into intestinal bleeding, early warning of intestinal cancer risk, and it is China's first home self-test fecal occult blood detection product
.

In January 2018, "Pupu Tube" obtained the second-class medical device registration certificate: 5 minutes insight into intestinal bleeding, early warning of intestinal cancer risk, and it is China's first home self-test fecal occult blood detection product
.

According to Nuohui’s 2022 semi-annual report, Pupuguan’s sales revenue in the first half of the year is expected to range from RMB66.
6 million to RMB70.
1 million, an increase of 125.
2% to 136.
8% over the same period in 2021
.

According to Nuohui’s 2022 semi-annual report, Pupuguan’s sales revenue in the first half of the year is expected to range from RMB66.
6 million to RMB70.
1 million, an increase of 125.
2% to 136.
8% over the same period in 2021
.

Chang Weiqing

Chang Weiqing Chang Weiqing

Colorectal cancer is the easiest cancer to prevent, but it is the cancer with the fastest growth rate of new cases among the top ten high-incidence cancers in China
.

Colorectal cancer is the easiest cancer to prevent, but it is the cancer with the fastest growth rate of new cases among the top ten high-incidence cancers in China
.

Because of the inconvenience of stool examination and the cumbersome preparation of colonoscopy, 95% of the physical examinations ignore the intestinal examination, which leads to the risk of cancer
.

Because of the inconvenience of stool examination and the cumbersome preparation of colonoscopy, 95% of the physical examinations ignore the intestinal examination, which leads to the risk of cancer
.

"Chang Weiqing" has solved this clinical pain point very well.
It is a product for early screening of colorectal cancer, and a product of "the first certificate for early screening of cancer in China", which was approved for marketing in November 2020
.

"Chang Weiqing" has solved this clinical pain point very well.
It is a product for early screening of colorectal cancer, and a product of "the first certificate for early screening of cancer in China", which was approved for marketing in November 2020
.

According to Nuohui's 2022 semi-annual report, Chang Weiqing's sales revenue in the first half of the year is expected to range from RMB 69.
4 million to RMB 76.
9 million, an increase of 388.
7% to 441.
5% over the same period in 2021
.

According to Nuohui's 2022 semi-annual report, Chang Weiqing's sales revenue in the first half of the year is expected to range from RMB 69.
4 million to RMB 76.
9 million, an increase of 388.
7% to 441.
5% over the same period in 2021
.

Youyou canal

Youyou canal

Helicobacter pylori, which is listed as a clear carcinogen, has infected nearly 700 million people in China
.

Helicobacter pylori, which is listed as a clear carcinogen, has infected nearly 700 million people in China
.

With the growing number of patients, "early detection and early treatment" is the key
.

With the growing number of patients, "early detection and early treatment" is the key
.

The Youyou Tube adopts the method of fecal antigen detection, with an integrated design of "pregnancy test stick": after sampling, insert the sampling stick back into the reagent tube, shake it for 10 seconds, and press the tube cap to read the result 10 minutes later
.

The Youyou Tube adopts the method of fecal antigen detection, with an integrated design of "pregnancy test stick": after sampling, insert the sampling stick back into the reagent tube, shake it for 10 seconds, and press the tube cap to read the result 10 minutes later
.

It is reported that the pylori tube is China's first Helicobacter pylori detection product suitable for "consumer self-test" and will be approved for marketing in January 2022
.

It is reported that the pylori tube is China's first Helicobacter pylori detection product suitable for "consumer self-test" and will be approved for marketing in January 2022
.

According to Nuohui's 2022 semi-annual report, since the launch of the product in January 2022, the sales revenue of Youyou Tube is expected to range from RMB 81 million to RMB 84.
5 million
.

According to Nuohui's 2022 semi-annual report, since the launch of the product in January 2022, the sales revenue of Youyou Tube is expected to range from RMB 81 million to RMB 84.
5 million
.

A few days ago, the three products of Nuohui Health have formed a "three-legged confrontation" situation, and the sales revenue is evenly matched
.

A few days ago, the three products of Nuohui Health have formed a "three-legged confrontation" situation, and the sales revenue is evenly matched
.

How to maintain the growth momentum?

How to maintain the growth momentum? How to maintain the growth momentum? How to maintain the growth momentum?

With the attraction of the "cake" in the 100 billion market, the domestic early screening field is poised to take off.
Siqin Medical, Herui Gene, Aide Bio.
.
.
How does Nuohui Health ride the wind and waves in the early screening field and maintain a strong development trend?

With the attraction of the "cake" in the 100 billion market, the domestic early screening field is poised to take off.
Siqin Medical, Herui Gene, Aide Bio.
.
.
How does Nuohui Health ride the wind and waves in the early screening field and maintain a strong development trend?

Judging from the 2021 annual report, the three products of Pupu Tube, Youyou Tube and Chang Weiqing have achieved strong performance growth.
Nuohui Health has a rapid commercialization momentum, which can continue to provide strong momentum for R&D:

Judging from the 2021 annual report, the three products of Pupu Tube, Youyou Tube and Chang Weiqing have achieved strong performance growth.
Nuohui Health has a rapid commercialization momentum, which can continue to provide strong momentum for R&D:

It is reported that in 2021, Nuohui Health will invest 58.
9 million yuan in research and development, a year-on-year increase of 132.
5%, and the number of patents will soar to 169
.

It is reported that in 2021, Nuohui Health will invest 58.
9 million yuan in research and development, a year-on-year increase of 132.
5%, and the number of patents will soar to 169
.

Judging from the products to be listed, as liver cancer and cervical cancer with the highest proportion of new cancers in my country, Novo's early screening products, glycoside Zhengqing and Gong Zhengqing, are also promising in the future:

Judging from the products to be listed, as liver cancer and cervical cancer with the highest proportion of new cancers in my country, Novo's early screening products, glycoside Zhengqing and Gong Zhengqing, are also promising in the future:

Glycine is expected to start a registered clinical trial by the end of 2022 at the earliest, and Gong Zhengqing will launch a large-scale prospective multi-center registered clinical trial with more than 10,000 people this year
.

Glycine is expected to start a registered clinical trial by the end of 2022 at the earliest, and Gong Zhengqing will launch a large-scale prospective multi-center registered clinical trial with more than 10,000 people this year
.

In addition, Nuohui Health actively promotes the expansion of overseas cooperation business.
In 2021, it will invest 30 million US dollars to establish a venture capital fund.
It has invested in foreign companies such as Arion Bio, Inc and Orbit Genomics, and actively incubates in vitro diagnostic companies and products
.

In addition, Nuohui Health actively promotes the expansion of overseas cooperation business.
In 2021, it will invest 30 million US dollars to establish a venture capital fund.
It has invested in foreign companies such as Arion Bio, Inc and Orbit Genomics, and actively incubates in vitro diagnostic companies and products
.

summary

summary summary summary

In the semi-annual report for two consecutive years, Nuohui Health, which has a growth rate of more than 300%, has made its first pot of gold by targeting the blue ocean of the cancer early screening market
.

In the semi-annual report for two consecutive years, Nuohui Health, which has a growth rate of more than 300%, has made its first pot of gold by targeting the blue ocean of the cancer early screening market
.

In the future, how to continue to make efforts in the early cancer screening market? It is worth thinking about how to reasonably apply the earned fees to the reinvestment of the R&D pipeline
.

In the future, how to continue to make efforts in the early cancer screening market? It is worth thinking about how to reasonably apply the earned fees to the reinvestment of the R&D pipeline
.